ES2473596T3 - Loci de inmunoglobulina humanizada - Google Patents

Loci de inmunoglobulina humanizada Download PDF

Info

Publication number
ES2473596T3
ES2473596T3 ES04778633.0T ES04778633T ES2473596T3 ES 2473596 T3 ES2473596 T3 ES 2473596T3 ES 04778633 T ES04778633 T ES 04778633T ES 2473596 T3 ES2473596 T3 ES 2473596T3
Authority
ES
Spain
Prior art keywords
spacer
human
humanized
locus
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04778633.0T
Other languages
English (en)
Spanish (es)
Inventor
Roland Buelow
Wim Van Schooten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutic Human Polyclonals Inc
Original Assignee
Therapeutic Human Polyclonals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Human Polyclonals Inc filed Critical Therapeutic Human Polyclonals Inc
Application granted granted Critical
Publication of ES2473596T3 publication Critical patent/ES2473596T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/107Rabbit
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES04778633.0T 2003-07-15 2004-07-15 Loci de inmunoglobulina humanizada Expired - Lifetime ES2473596T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48773303P 2003-07-15 2003-07-15
US487733P 2003-07-15
PCT/US2004/023226 WO2005007696A2 (en) 2003-07-15 2004-07-15 Humanized immunoglobulin loci

Publications (1)

Publication Number Publication Date
ES2473596T3 true ES2473596T3 (es) 2014-07-07

Family

ID=34079388

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04778633.0T Expired - Lifetime ES2473596T3 (es) 2003-07-15 2004-07-15 Loci de inmunoglobulina humanizada

Country Status (10)

Country Link
US (4) US7585668B2 (cg-RX-API-DMAC7.html)
EP (1) EP1644417B1 (cg-RX-API-DMAC7.html)
JP (2) JP2007537704A (cg-RX-API-DMAC7.html)
CN (2) CN103205436B (cg-RX-API-DMAC7.html)
AU (1) AU2004257292A1 (cg-RX-API-DMAC7.html)
CA (1) CA2532117C (cg-RX-API-DMAC7.html)
ES (1) ES2473596T3 (cg-RX-API-DMAC7.html)
IL (1) IL172885A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06000562A (cg-RX-API-DMAC7.html)
WO (1) WO2005007696A2 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
CN103205436B (zh) * 2003-07-15 2016-05-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
US20090053210A1 (en) 2006-09-01 2009-02-26 Roland Buelow Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
SG174053A1 (en) 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
PT2336329E (pt) 2007-06-01 2012-12-24 Omt Inc Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
EP2185692A4 (en) * 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
CN101868144A (zh) * 2007-08-14 2010-10-20 奥瑞金治疗公司 具有失活的内源基因座的转基因鸡
EP2108696A1 (en) * 2008-04-10 2009-10-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Cis-acting diversification activator and method for selective diversification of nucleic acids
US20110314563A1 (en) * 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
NO2792236T3 (cg-RX-API-DMAC7.html) * 2009-07-08 2018-04-14
JP5756802B2 (ja) * 2009-08-13 2015-07-29 クリスタル バイオサイエンス インク.Crystal Bioscience Inc. 最小cdrを有する抗体を産生するトランスジェニック動物
US8865462B2 (en) 2010-01-20 2014-10-21 Crystal Bioscience Inc. Sustained culture of avian gonocytes
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
ES2641920T3 (es) 2010-03-31 2017-11-14 Ablexis, Llc Ingeniería genética de animales no humanos para la producción de anticuerpos quiméricos
ME02902B (me) 2010-06-22 2018-04-20 Regeneron Pharma Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
CN102250239B (zh) * 2011-06-13 2013-04-17 中国农业科学院哈尔滨兽医研究所 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2758535B1 (en) * 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
KR20250021626A (ko) 2011-10-17 2025-02-13 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
BR112014015238B1 (pt) 2011-12-20 2022-11-16 Regeneron Pharmaceuticals, Inc Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6
WO2013092720A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
HRP20192218T1 (hr) * 2012-02-01 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
LT2883449T (lt) 2012-03-16 2018-05-10 Regeneron Pharmaceuticals, Inc. Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
MX364449B (es) 2012-06-12 2019-04-26 Regeneron Pharma Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos.
NZ703973A (en) 2012-08-03 2018-04-27 Sab Llc Complex chromosome engineering for production of human antibodies in transgenic animals
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
EP2970437A1 (en) * 2013-03-13 2016-01-20 Regeneron Pharmaceuticals, Inc. Common light chain mouse
ES2942413T3 (es) * 2013-03-13 2023-06-01 Regeneron Pharma Ratones que expresan un repertorio limitado de cadenas ligeras de inmunoglobulina
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠IgE量高出許多的人源化IgE之基因轉殖動物
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 単一ドメイン結合タンパク質を作る非ヒト動物
DK3138903T3 (da) * 2014-05-02 2022-04-19 Chiome Bioscience Inc Celler til produktion af humant antistof
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2017072208A1 (en) * 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Transgenic rabbit with common light chain
DK4082334T3 (da) * 2016-11-04 2025-06-02 Regeneron Pharma Ikke humane dyr med et modificeret immunglobulin-lambda-letkædelocus
EP3549228B1 (en) 2016-12-05 2020-04-15 Koninklijke Philips N.V. Foreign object detection in a wireless power transfer system
KR102777514B1 (ko) 2017-01-19 2025-03-06 옴니에이비 오퍼레이션스, 인코포레이티드 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
CN111511400B (zh) 2017-12-29 2025-08-29 豪夫迈·罗氏有限公司 抗vegf抗体及其使用方法
JP7779655B2 (ja) * 2018-03-21 2025-12-03 クリスタル バイオサイエンス インコーポレイテッド ヒト型抗体を産生するトランスジェニックニワトリ
EP3990492A1 (en) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN110540996B (zh) * 2019-08-29 2022-01-28 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用
EP4075965A1 (en) * 2019-12-18 2022-10-26 Bristol-Myers Squibb Company Bcr transgenic mice with a common leader sequence
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
CN114854901B (zh) * 2022-06-22 2025-11-07 华南农业大学 与苦瓜全雌性状共分离的分子标记、引物及其应用
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8212291A (en) 1990-07-10 1992-02-04 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
WO1992003918A1 (en) * 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
WO2000046251A2 (en) 1999-02-05 2000-08-10 Buelow Jens Ulrich Human polyclonal antibodies from transgenic nonhuman animals
EP1190042A2 (en) 1999-06-04 2002-03-27 Tranxenogen, Inc. Methods for manipulating the avian genome
AU7491800A (en) 1999-09-15 2001-04-17 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
US7129084B2 (en) * 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
DE60327537D1 (de) 2002-06-26 2009-06-18 Transgenrx Inc Genregulation in transgenen tieren unter verwendung eines vektors auf transposonbasis
CN103205436B (zh) * 2003-07-15 2016-05-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
EP1782360A4 (en) 2004-08-27 2009-03-18 Medic4All Ag METHOD AND SYSTEM FOR THE USE OF A MOBILE DEVICE AS A PORTABLE PERSONAL TERMINAL FOR MEDICAL INFORMATION
US20110077965A1 (en) 2009-09-25 2011-03-31 Cerner Innovation, Inc. Processing event information of various sources
US20120306653A1 (en) 2011-06-02 2012-12-06 Nokia Siemens Networks Oy Medical sensor
US20130021154A1 (en) 2011-07-21 2013-01-24 Solomon Clifford T Medical parameters notification system

Also Published As

Publication number Publication date
CN103205436A (zh) 2013-07-17
MXPA06000562A (es) 2006-03-30
IL172885A0 (en) 2006-06-11
US20100205682A1 (en) 2010-08-12
CA2532117C (en) 2012-07-10
JP6017763B2 (ja) 2016-11-02
WO2005007696A3 (en) 2005-11-03
EP1644417A2 (en) 2006-04-12
US20060026696A1 (en) 2006-02-02
USRE47131E1 (en) 2018-11-20
EP1644417B1 (en) 2014-04-30
US8410333B2 (en) 2013-04-02
CN1852925A (zh) 2006-10-25
US20130189774A1 (en) 2013-07-25
US7585668B2 (en) 2009-09-08
JP2007537704A (ja) 2007-12-27
AU2004257292A1 (en) 2005-01-27
CN103205436B (zh) 2016-05-25
CA2532117A1 (en) 2005-01-27
US8652842B2 (en) 2014-02-18
WO2005007696A2 (en) 2005-01-27
JP2011182801A (ja) 2011-09-22

Similar Documents

Publication Publication Date Title
ES2473596T3 (es) Loci de inmunoglobulina humanizada
AU2001284703B2 (en) Production of humanized antibodies in transgenic animals
JP6705650B2 (ja) ヒトイディオタイプを有するげっ歯類抗体をコードするポリヌクレオチド及びそれを含む動物
US20050153392A1 (en) Transgenesis with humanized immunoglobulin loci
EP1690934A2 (en) Generation of xenogeneic antibodies
AU2001284703A1 (en) Production of humanized antibodies in transgenic animals
JP5188969B2 (ja) ヒト化免疫グロブリンを発現するトランスジェニック動物におけるb細胞アポトーシスの抑制
US20240373832A1 (en) Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
US20040158880A1 (en) Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies
ZA200301723B (en) Production of humanized antibodies in transgenic animals.